University Hospital Ulm, Otolaryngology & Head and Neck Surgery
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Laban, Simon
PATHOS, NCT02215265 / 2014-003392-32: Post-operative Adjuvant Treatment for HPV-positive Tumours

Recruiting
3
1100
Europe, US, RoW
Cisplatin, Postoperative radiotherapy
Lisette Nixon, UNICANCER, AdventHealth, University of Leipzig, Princess Alexandra Hospital, Brisbane, Australia, Stanford University
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
10/26
04/27
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
KEYNOTE-C34, NCT04811027 / 2021-000055-39: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Checkmark Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Oct 2021 - Oct 2021: Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Active, not recruiting
2
171
Europe, US, RoW
eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475
Immutep S.A.S., Merck Sharp & Dohme LLC
HNSCC
03/24
03/25
ELOS, NCT06137378: European Larynx Organ Preservation Study () [MK-3475-C44]

Recruiting
2
140
Europe
KEYTRUDA®, Pembrolizumab, MK-3475
University of Leipzig, University of Göttingen, University of Jena, University of Cologne, University of Ulm, University of Regensburg, Wuerzburg University Hospital, Technical University of Munich, Ernst von Bergmann Hospital, Universitätsmedizin Mannheim, University of Kiel
Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV, Laryngeal Squamous Cell Carcinoma, Laryngectomy; Status, Laryngeal Cancer, Laryngeal Neoplasms
12/28
12/30
NCT05433116: Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Recruiting
2
50
Europe
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Universität des Saarlandes
Head and Neck Squamous Cell Carcinoma
09/25
09/26
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Eckstein, Markus
NCT05433116: Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Recruiting
2
50
Europe
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Universität des Saarlandes
Head and Neck Squamous Cell Carcinoma
09/25
09/26

Download Options